Caliber Wealth Management LLC KS Invests $1.26 Million in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Caliber Wealth Management LLC has invested approximately $1.26 million in IQVIA Holdings Inc., acquiring 7,130 shares during the first quarter, as reported in a recent 13F filing.
• In the latest earnings report, IQVIA exceeded analysts' expectations with an EPS of $2.81 and revenue of $4.02 billion, marking a 5.3% year-over-year increase.
• Various research firms have adjusted their ratings on IQVIA, with HSBC downgrading the stock while UBS and Barclays both raised their price targets, reflecting a consensus rating of "Moderate Buy".

Caliber Wealth Management LLC KS bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,130 shares of the medical research company's stock, valued at approximately $1,257,000.

Several other institutional investors and hedge funds have also made changes to their positions in IQV. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the last quarter. Sei Investments Co. raised its holdings in shares of IQVIA by 4.7% in the fourth quarter. Sei Investments Co. now owns 86,503 shares of the medical research company's stock valued at $16,999,000 after acquiring an additional 3,844 shares in the last quarter. LPL Financial LLC raised its holdings in shares of IQVIA by 1.4% in the fourth quarter. LPL Financial LLC now owns 96,506 shares of the medical research company's stock valued at $18,964,000 after acquiring an additional 1,311 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of IQVIA in the fourth quarter valued at about $276,000. Finally, Zions Bancorporation N.A. raised its holdings in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IQV. Robert W. Baird lifted their price objective on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. UBS Group boosted their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Cowen reiterated a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Mizuho set a $225.00 price target on IQVIA and gave the stock an "outperform" rating in a research note on Friday, July 25th. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Trading Down 0.7%

Shares of IQV traded down $1.32 during midday trading on Wednesday, reaching $193.23. The company had a trading volume of 266,676 shares, compared to its average volume of 2,031,212. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The stock has a market cap of $32.85 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.17 and a beta of 1.30. The firm has a 50 day simple moving average of $159.17 and a 200-day simple moving average of $170.16. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the business posted $2.64 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.